Journal
ACTA NEUROLOGICA SCANDINAVICA
Volume 122, Issue -, Pages 12-17Publisher
WILEY
DOI: 10.1111/j.1600-0404.2010.01369.x
Keywords
acetylcholine esterase inhibitors; exercise test; fatigue; myasthenia gravis; pulmonary function
Categories
Ask authors/readers for more resources
Objectives - Myasthenia gravis (MG) is an autoimmune disease of neuromuscular synapses, characterized by muscular weakness and reduced endurance. Remission can be obtained in many patients. However, some of these patients complain of fatigue. The aim of this study was to assess exercise capacity and lung function in well-regulated MG patients. Patients and methods - Ten otherwise healthy MG patients and 10 matched controls underwent dynamic spirometry, and a ramped symptom-limited bicycle exercise test. Spirometric variables included forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and maximum voluntary ventilation (MVV). Exercise variables included maximal oxygen uptake (VO2 max), anaerobic threshold (VO2 AT) maximum work load (W), maximum ventilation (VE max), and limiting symptom. Results - Myasthenia gravis patients had significantly lower FEV1/FVC ratio than controls. This was more marked in patients on acetylcholine esterase inhibitors. On the contrary, patients not using acetylcholine esterase inhibitors had a significantly lower exercise endurance time. Conclusion - Well-regulated MG patients, especially those using pyridostigmine, tend to have an airway obstruction. The modest airway limitation might be a contributing factor to their fatigue. Patients who are not using acetylcholinesterase inhibitor seem to have diminished exercise endurance in spite of their clinically complete remission.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available